Address: ‘Eski Büyükdere Cad. Dilaver Sok. NO:4 34418
Oto Sanayi 4 Levent / İstanbul
,Turkey
Tel: +90 212 316 78 00
Web: http://www.aliraif.com.tr/
Ali Raif was founded under the name of Ali Raif ve Şeriki (Ali Raif and Associate) in 1928. Then company was reorganized in order to trade in pharmaceuticals industry by Muzaffer Turhan in 1963. Since 1983, the company has had operations under the name of Ali Raif Pharmaceutical Inc. Co.
Ali Raif was marketing pharmaceuticals as a licensee of multinational companies in the early years of its foundation. Then the company became one of the leading companies of the Turkish Pharmaceutical Industry starting to import finished pharmaceuticals and to produce and market generic pharmaceuticals.
After Ali Raif commenced generic pharmaceuticals licensing, producing and marketing, export opportunities started to arise in parallel to them. Export activities started with Azerbaijan and Georgia has enlarged with EU countries in 2003. Since 2005 they have speeded up greatly.
The countries that have been export are England, Portugal, Hungary, Azerbaijan, Georgia, The Philippines, Bulgaria, Spain, Algeria, and Poland.
Ali Raif has nearly 150 pharmaceuticals with their forms in therapeutic fields such as cardiovascular, diabetics, gastrointestinal, analgesic, anti-inflammatory, anti-flu, antihistaminic, central nervous system.
Headquarters and production facilities are located in İkitelli, İstanbul, has totally 10 regional offices in Turkey.
Evren Özlü, General Manager of Turkey and Sub-Saharan Africa at Boehringer Ingelheim, discusses the company’s double-digit growth in the last year, and its leading position as one of the fastest…
Polifarma is a Turkish pharma company dedicated to the hospital sector and biosimilars. Its chairman, Ufuk Kumrulu, explains how the company has managed to become a top two company in…
Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer…
The president of the Investment Office of the Presidency of the Republic of Turkey, Burak Dağlıoğlu, outlines the country’s current economic situation after posting the second-highest GDP growth among G20…
Muzaffer Bal, CEO of Ali Raif, a Turkish generics firm, highlights the company’s new investment in a manufacturing plant, their refusal to follow the trend of Turkish local companies investing…
Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their position as the licensing and CMO partner of choice for multinational companies…
Ilko Pharmaceuticals is a family-owned Turkish generics and biosimilars company. General Manager Hatice Öncel explains the company’s investment in biosimilars in collaboration with South Korea’s Genexine and how recent success…
Dr Hamdi Akan, head of Turkey’s Clinical Research Association, dives into the country’s opportunities and barriers to become a clinical trials hub, including the world-class infrastructure and the need for…
İsmail Yormaz, Recordati’s VP and regional director for south-east, highlights how the Milan-based company has become a shining example of a successful localization strategy, upcoming launches and investments, as well…
Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over 95 percent of the population. The effort, part of the…
Takeda’s general manager for Turkey, Şeyda Atadan Memiş, reflects on the Japanese giant’s ambitions in Turkey at a pivotal moment when the Shire integration has been completed. Atadan discusses how…
TITCK is the regulatory agency in charge of ensuring the safety of medicines, health products, cosmetics, and personal care products in Turkey. Its recently appointed president, Dr Tolga Karakan, discusses…
See our Cookie Privacy Policy Here
